Last reviewed · How we verify
Urocortins 2 & 3-Effects on Forearm Arterial Blood Flow in Patients With Heart Failure
Despite modern advances in treatment, heart failure continues to carry a poor prognosis with high morbidity and mortality rates. Hence, there remains a major interest in the development of novel therapeutic agents for this debilitating condition. Urocortins have recently shot into limelight with their potential role in the pathophysiology and treatment of heart failure. Recent studies by the investigators group (REC no: 09/S1103/41) have confirmed that Urocortin 2 and 3 are potent arterial vasodilators, the effects of which are reproducible and well tolerated in healthy male volunteers. Previous studies using heart failure models in animals1-7, as well studies in heart failure patients (Urocortin 2), suggest that there is great scope for Urocortins as novel biomarkers and as potential therapeutic agents in heart failure. With this in mind, the investigators wish to study the local vasomotor effects of these peptides in greater detail in patients with heart failure.
Details
| Lead sponsor | University of Edinburgh |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 22 |
| Start date | 2012-05 |
| Completion | 2012-07 |
Conditions
- Heart Failure
- Endothelium
Interventions
- Urocortin 2, Urocortin 3 and Substance P
Primary outcomes
- Forearm blood flow — 3 hours
Difference between forearm blood flow in response to doses of Ucn2, Ucn3 and Substance P between heart failure patients and healthy controls.
Countries
United Kingdom